Abbvie ((ABBV)), Abbvie (($CC:ABBV.CUR)) announced an update on their ongoing clinical study.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
AbbVie has initiated a Phase 3 clinical study titled ‘A Phase 3, Multicenter, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Tolerability of Ubrogepant for the Preventive Treatment of Menstrual Migraine With an Open-Label Extension.’ The study aims to assess the safety and effectiveness of ubrogepant in treating menstrual migraine, a condition characterized by migraine attacks around the menstrual period.
The intervention being tested is ubrogepant, an investigational oral drug intended for the short-term prevention of menstrual migraines. Participants will receive either ubrogepant or a placebo to evaluate its efficacy and safety.
This interventional study employs a randomized, sequential intervention model with quadruple masking (participant, care provider, investigator, outcomes assessor) to ensure unbiased results. The primary purpose is treatment, focusing on reducing the frequency and severity of menstrual migraines.
The study began on September 10, 2024, with a primary completion date projected for 2025. The latest update was submitted on July 15, 2025, indicating ongoing recruitment and progress.
This study could significantly impact AbbVie’s market position by potentially expanding its product portfolio in the migraine treatment market. Positive results may enhance investor confidence and influence stock performance, especially in comparison to competitors in the migraine treatment industry.
The study is ongoing, with further details available on the ClinicalTrials portal.